Clinical Pharmacology & RCT Meta-Analysis Workbench

Magnesium Clinical Trial & Bioavailability Evidence Map

Evaluate elemental yield, 24-hour pharmacokinetic partitioning, GI osmotic load, and trial responder odds across 6 formulations based on baseline dietary status.

24-Hour Pharmacokinetic & Intracellular Uptake Simulator Dynamic Renal Clearance Threshold: 0.95 mmol/L
Serum Mg²⁺ Concentration Intracellular / Tissue Partition Renal Excretion Filtration Cutoff
RCT Meta-Analysis Efficacy & Trial Responder Odds Analysis: Sleep Latency RCT Meta-Analysis
Predicted Responder Rate Cohen's d: 0.54 (Mod)
64% Responder Rate

High probability of clinical response due to baseline dietary deficiency (<250 mg/d) paired with high bioavailable chelate.

Physiological Target Mechanism
GABA-A Agonism & Melatonin Synergism

Mg²⁺ acts as a natural NMDA receptor blocker and allosteric modulator of GABA-A receptors, reducing central nervous system hyperexcitability and facilitating sleep spindle onset.

Formulation Bioavailability & Clinical Tolerability Matrix
Compound Elemental % Relative Abs BBB Entry GI Side Effects Primary Clinical Trial Niche
Enjoy this tool? Build your own with Super